Silliver Tablet Uses: What Silymarin Liver Support Means and What It Does Not Prove

Short answer

• Silliver is a silymarin tablet. The name refers to a tablet product built on silymarin, the mixture of plant compounds extracted from milk thistle seeds, marketed for liver support.
• Liver support is not a proven treatment claim. The National Center for Complementary and Integrative Health (NCCIH) concludes there is not enough high quality evidence to reach definite conclusions about milk thistle for any health condition.
• The best trials were negative. Two trials funded by NCCIH, one in hepatitis C and one in nonalcoholic steatohepatitis, a progressive form of fatty liver disease, did not show benefit from silymarin. A Cochrane systematic review found no significant effect on death, liver disease complications, or liver structure.
• Some smaller trials show modest enzyme changes. A number of trials report small reductions in liver enzyme markers such as ALT and AST. A change in a blood marker is not the same as proof of better long term liver outcomes.
• It is generally well tolerated, not risk free. Reported side effects are usually digestive, such as bloating, nausea, and diarrhea, and allergic reactions can occur, especially in people allergic to plants in the same family as ragweed. Little is known about safety in pregnancy or while breastfeeding.
• Supplements are not approved like medicines in the United States. The Food and Drug Administration does not approve dietary supplements for safety or effectiveness before they are sold, so a liver support claim on a label is not evidence that the claim was proven.
• Liver symptoms need a doctor, not a supplement. Yellowing of the skin or eyes, a swollen abdomen, unusual bruising or bleeding, confusion, vomiting blood, or black stools need prompt medical care.

Introduction

People searching for Silliver tablet uses, sometimes typing the name as silivers, usually want a simple answer to a simple question: what is this tablet for? The short version is that Silliver is a tablet name associated with silymarin, the active extract taken from the seeds of the milk thistle plant, and products of this kind are marketed for liver support. Everything important in this article follows from the gap between those last two words and what they are often taken to mean. Liver support is a marketing phrase. It is not the same as treating liver disease, reversing liver damage, or protecting the liver in a proven way, and the research record behind silymarin is mixed, modest, and in its most rigorous trials negative.

This article explains, in general terms, what silymarin is, why scientists found it plausible enough to study, what human trials and systematic reviews actually found, why supplement labels can claim more than trials have shown, what safety and interaction cautions apply, and which liver symptoms should send you to a doctor promptly rather than to a supplement shelf. It is general information only. It gives no dose, no prescription recommendation, and no treatment recommendation for any individual. Whether a silymarin product is suitable for you, and whether it fits safely alongside medicines you already take, are questions for a doctor or pharmacist who knows your full medical history. Do not start, stop, or change any treatment for a liver condition on the strength of a general article.

One framing point matters throughout. Silliver is a brand name used in some markets, and the details that attach to a brand, such as whether it is sold as a medicine or as a supplement, its exact formulation, and its local labeling, vary by country. The evidence discussed here is about silymarin and milk thistle as ingredients, because that is what the research studied. Ingredient level evidence is the honest level at which to judge any product built on that ingredient.

Silliver, Silymarin, and Milk Thistle: Three Names, One Story

Confusion starts with the names, because three different terms get used almost interchangeably in shops and search results, and they are not the same thing.

Milk thistle is the plant. Its scientific name is Silybum marianum. It is a tall plant with large purple flowers, native to Europe, and it was brought to North America by early colonists, according to NCCIH. Historically it was used for liver disorders, and that traditional use is the origin of its modern reputation.

Silymarin is the extract. The main constituent of milk thistle extract is silymarin, which is not a single chemical but a mixture of compounds called flavonolignans, taken from the seeds of the plant. The best studied of these compounds is silybin, also called silibinin. When researchers run a trial of milk thistle, they are almost always testing a silymarin extract, because that is the concentrated, standardizable part of the plant.

Silliver is a product name. A tablet sold under the Silliver name is a commercial preparation whose active ingredient is presented as silymarin. A brand name tells you who sells the product. It does not tell you, by itself, how much silymarin a tablet contains, how the extract was standardized, or what evidence supports the claims on its box. Those details live on the label and in the research on the ingredient, which is why this article spends most of its length on silymarin itself.

This naming pattern is common across pharmacy shelves, where a familiar brand name can hide a much less familiar active ingredient. Readers working through another brand name medicine may find the same discipline useful in our explainer on Ulsanic syrup uses, which separates a product name from the ingredient and the evidence in the same way. The habit to build is simple: judge the ingredient and its evidence first, and treat the brand as packaging.

What Silymarin Is, and Why Scientists Studied It

Silymarin attracted research attention for a legitimate reason. In laboratory and animal studies, it behaves in ways that look relevant to liver injury. Reviews of that preclinical work describe antioxidant activity, meaning it can neutralize unstable molecules that damage cells, along with anti-inflammatory and antifibrotic effects in animal models, and an ability to stabilize liver cell membranes. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) resource LiverTox summarizes the same picture: in cell culture and animal models, silymarin has been shown to prevent or lessen acute liver injury from a range of toxins.

That is a real scientific starting point, and it explains decades of trials. It is not, on its own, evidence of benefit in people. Laboratory and animal findings regularly fail to translate into human benefit, because a compound that protects cells in a dish may be absorbed poorly, broken down quickly, or present in the body at far lower levels than the experiment used. Silymarin illustrates the problem directly. It is poorly absorbed from the gut in its standard form, which is one reason manufacturers sell a variety of formulations, including standardized extracts and enhanced preparations designed to improve absorption.

Product variation then feeds back into the research problem. Trials have used different extracts, different standardizations, different formulations, and different treatment lengths, in different groups of patients. When trial results disagree, and for silymarin they often do, part of the explanation is that the trials were not all testing the same thing in the same way. A careful reader should hold two ideas at once: the underlying idea behind silymarin is plausible, and plausibility is the beginning of a research question, not the end of one.

What the Human Evidence Actually Shows

The fairest summary of the human evidence is the one NCCIH gives: results from clinical trials of milk thistle for liver diseases, including alcohol related liver disease, hepatitis B and C, fatty liver disease, and liver problems caused by chemotherapy, low oxygen, or toxins, have been conflicting or too limited to allow conclusions to be reached. Unpacking that sentence condition by condition shows why stronger claims are not justified.

Hepatitis C: the most rigorous test, and a clear negative

Hepatitis C is where silymarin faced its most rigorous test. NCCIH states plainly that no dietary supplement has been shown to be effective for hepatitis C. Several studies of silymarin supplements in people with hepatitis C did not find beneficial effects. A 2014 evaluation of five studies, covering 389 participants, found no benefit: silymarin did not improve liver function and did not lower levels of the hepatitis C virus.

The largest of these trials was funded by NCCIH together with NIDDK and published in JAMA in 2012. It enrolled 154 people with chronic hepatitis C who had not responded to standard drug treatment, and it gave silymarin at higher than usual doses for 24 weeks. The result was that silymarin was no better than a placebo, an inactive substance, at improving a key measure of liver function. That detail matters, because it answers the common response that negative trials simply used too little. In this trial, more did not work better. Modern hepatitis C care rests on antiviral medicines that cure the infection, and nothing in the silymarin record challenges that.

Fatty liver disease and steatohepatitis

Fatty liver disease is the condition for which liver support marketing is now most often aimed, and the evidence here is best described as a modest signal surrounded by uncertainty. A systematic review and meta-analysis of 23 trials looked at silymarin and the liver enzymes ALT, AST, and a third marker, and the wider trial literature includes studies reporting reductions in those enzymes. Enzyme reductions are the strongest recurring finding in the silymarin literature, and they should be described accurately rather than dismissed.

Two cautions follow. First, a second trial funded by NCCIH, this time in nonalcoholic steatohepatitis, the progressive inflammatory form of fatty liver disease, did not show benefit from silymarin. When the best funded and most carefully run trials are negative while smaller and shorter trials report marker changes, the cautious reading is that any effect is small and unproven where it counts. Second, an enzyme is a marker, not an outcome. ALT and AST rise when liver cells are stressed, so a fall in those numbers is encouraging on paper, but patients and doctors ultimately care about whether scarring progresses, whether complications occur, and whether people live longer and feel better. The silymarin literature does not show convincing effects on those harder outcomes.

Alcohol related and viral liver disease: the Cochrane verdict

For alcohol related liver disease and hepatitis B and C taken together, the reference point is the Cochrane systematic review by Rambaldi and colleagues. The Cochrane review pooled 13 randomized trials covering 915 patients with alcoholic and or hepatitis B or C virus liver diseases. It found that milk thistle, compared with placebo or no intervention, had no significant effect on mortality, on complications of liver disease, or on liver histology, meaning the physical state of liver tissue. One result looked favorable at first glance: liver related mortality was significantly lower with milk thistle when all trials were counted together. That apparent benefit disappeared when the analysis was restricted to the high quality trials. The reviewers concluded that the results question the beneficial effects of milk thistle for these conditions and highlight the lack of high quality evidence.

That pattern, a benefit that survives only in lower quality trials, is one of the most informative patterns in medical research. It usually means the benefit was an artifact of weak trial design rather than a property of the treatment. It is the single strongest reason this article will not describe silymarin as proven liver protection.

What about detox claims?

Claims that a silymarin product detoxes or cleanses the liver go beyond even the most generous reading of the trials. The liver is itself the organ that processes and neutralizes substances from the blood. That is its ordinary, continuous work, and it does not need a supplement to switch it on. No trial evidence shows that silymarin cleanses the body in the broad marketing sense, removes unspecified toxins, or offsets the effects of alcohol. If you drink heavily, the intervention with evidence behind it is drinking less, supported by medical care where stopping is difficult. A tablet taken alongside unchanged drinking is not a shield, and presenting it as one is the most harmful version of the liver support claim, because it can delay the change that actually helps. For background on the organ at the center of all of this, our anatomy explainer on where the liver is located in the body covers what the liver does and where it sits.

Why the Label Can Say More Than the Trials Show

Many readers reasonably assume that a health claim printed on a box sold in a pharmacy must have been checked before sale. In the United States, for dietary supplements, that assumption is wrong, and understanding the actual system explains how liver support language reaches shelves without proof behind it.

Under the Dietary Supplement Health and Education Act of 1994, dietary supplements are regulated as a category of food rather than as drugs. The practical consequences are these. The Food and Drug Administration does not approve dietary supplements for safety or effectiveness before they are sold, and it does not approve their labeling in advance. Manufacturers are responsible for making sure their products are safe and that their label claims are truthful and not misleading, but they do not have to prove effectiveness to the agency before marketing. The FDA role is mainly after products reach the market: it inspects manufacturing facilities, monitors reports of harm, and can act against products that are unsafe or misbranded.

Within that system, phrases like supports liver health are known as structure and function claims. They describe an effect on the normal structure or function of the body, and they can be used without the kind of premarket proof a drug would need. When a supplement carries such a claim, its label must also carry a disclaimer stating that the claim has not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease. That small print is not boilerplate. It is the label telling you, accurately, that the headline claim beside it was not verified by the regulator.

Two qualifications keep this picture honest. First, rules differ by country, and a product sold under the Silliver name in a given market may be regulated there as a medicine, as a supplement, or under another category, with different labeling and availability rules. Local pharmacy guidance is the reliable source for the status of a specific product where you live. Second, weak premarket regulation does not mean every supplement is worthless or dangerous. It means the burden of judgment sits with the buyer and their clinicians to an unusual degree, which is exactly why the label reading skills in the next section matter.

How to Read a Silymarin Supplement Label

A label cannot tell you whether silymarin will help you, because the evidence does not answer that question for any individual. It can tell you what you would actually be taking, and whether the product is presented honestly. Work through these checks.

Find the active ingredient statement first. Look for silymarin or milk thistle extract in the supplement facts panel, and note whether the amount given is for the whole extract or for silymarin itself, since those are different numbers. Extracts are often described as standardized to a percentage of silymarin. A higher percentage sounds stronger, but standardization describes consistency of composition, not proven benefit.

Separate the claim from the evidence. Note any structure and function wording, such as supports liver health, and then look for the required disclaimer nearby. Its presence confirms the claim was not evaluated by the FDA. Treat words like detox, cleanse, repair, and regenerate as marketing signals rather than findings, because no human evidence supports them for silymarin.

Check the rest of the formula. Many liver products combine several herbs and nutrients. Each added ingredient brings its own evidence questions and its own interaction potential, and combination products are harder for a pharmacist to assess than a single ingredient product. A long proprietary blend that hides individual amounts is a reason for extra caution, not extra confidence.

Look for quality marks with realistic expectations. Independent testing seals can indicate that a sample was checked for identity and certain contaminants. They do not certify that the product works, and no seal converts an unproven claim into a proven one.

Finally, treat the label as the start of a conversation. Take the box, or a photo of its facts panel, to a pharmacist before you buy or before you take a first tablet if you already have it. That check takes minutes and covers the questions a label cannot answer, above all whether the product fits with your medicines and conditions.

Safety, Side Effects, and Interactions

The safety picture for milk thistle in trials is generally reassuring, and it should still be handled with care. NCCIH reports that milk thistle taken by mouth appears to be well tolerated, and clinical trial evidence in people with liver diseases suggests the same. LiverTox, the NIDDK liver injury resource, adds a specific and useful point: milk thistle has not been implicated in causing liver injury, despite wide use in people with and without liver disease. A supplement taken for the liver that is not itself a known cause of liver injury is a better starting point than many alternatives on the same shelf.

Well tolerated in trials is not the same as safe for every person. The commonly reported side effects are digestive: a laxative effect, nausea, diarrhea, abdominal bloating and pain. Allergic reactions occur occasionally. Milk thistle belongs to the aster plant family, the same broad family as ragweed, daisies, and chrysanthemums, so people with allergies to those plants have a specific reason to be cautious and to raise it with a clinician before use.

Three groups should treat medical advice as a precondition rather than a formality. Little is known about whether milk thistle is safe during pregnancy or while breastfeeding, so the honest position is that safety there is unestablished. People with diabetes should know that a small number of studies suggest milk thistle extracts may help control blood sugar, which is a research finding rather than a reason to self treat, and it means a silymarin product could matter alongside diabetes medicines. People with serious liver disease should not add any supplement without their liver team knowing, because their margin for error is smaller and because a new product can complicate the interpretation of their blood tests.

Interactions deserve their own paragraph because they are the risk most often skipped. LiverTox notes that silymarin affects certain drug processing enzymes and transporters in laboratory studies, while finding little evidence that it causes clinically significant interactions in practice. NCCIH gives the practical instruction that follows from that uncertainty: talk with your health care provider about any complementary approach you use, and specifically before combining milk thistle with medicines. A pharmacist can check a named product against your current medicine list, including blood thinners, diabetes medicines, and anything processed by the liver. That check is free at most pharmacies, takes little time, and is the single most useful safety step available before use.

When Liver Symptoms Need a Doctor Promptly

A supplement article is the wrong place to manage symptoms, so this section exists to redirect. Liver disease is often quiet in its early stages, and the National Institute of Diabetes and Digestive and Kidney Diseases notes that symptoms of advanced scarring, called cirrhosis, may not appear until the liver is badly damaged. When symptoms do appear, they deserve medical assessment on their own terms, not a trial of a liver support product to see whether they fade.

Book a prompt appointment with a doctor if you notice yellowing of the skin or the whites of the eyes, known as jaundice, dark urine or pale stools, persistent itching, swelling of the legs or abdomen, bruising or bleeding more easily than usual, ongoing nausea with poor appetite, or weight loss you did not intend. NIDDK lists tiredness, itching, poor appetite, weight loss, and nausea among the earlier symptoms of cirrhosis, with jaundice, fluid swelling, easy bruising, and confusion appearing as the condition worsens. None of these symptoms proves liver disease on its own, and several have many possible causes. That is an argument for assessment, not for waiting.

Some presentations are emergencies rather than appointments. Vomiting blood, passing black or bloody stools, new confusion or unusual drowsiness, or a rapidly swelling abdomen in someone with known liver disease can signal serious complications and need emergency care the same day. A supplement has no role in any of these situations. Getting assessed quickly does.

The same redirect applies to abnormal blood results. If a routine test flags raised liver enzymes, the productive next steps are a doctor reviewing your medicines, alcohol intake, weight, and metabolic risks, and arranging follow up testing. Adding silymarin before that review can muddy the picture by changing the very markers being watched, without any proven benefit to show for it.

Making a Sensible Decision

If you are considering a product like Silliver after reading the evidence, a sensible decision process looks like this. Start with the reason. If the reason is a diagnosed liver condition, the decision belongs inside your existing care, with the doctor managing that condition. If the reason is a symptom, get the symptom assessed first. If the reason is general unease after reading marketing, recognize that no supplement has been shown to maintain liver health in a person whose liver is already healthy, and that the measures with real evidence behind them are unglamorous: drinking less or not at all, maintaining a healthy weight, keeping up hepatitis vaccinations, and using medicines, including everyday pain relievers, within their labeled limits and with pharmacist advice where you are unsure.

If, after that, you still want to discuss silymarin, bring specifics to the conversation: the exact product, its facts panel, your full medicine list, and your conditions, including allergies and diabetes. Ask directly what benefit is realistic, what interactions were checked, and what would tell you to stop. That conversation, with a doctor or pharmacist who can see the whole picture, is worth more than any claim printed on a box.

Frequently Asked Questions

What is Silliver tablet used for? Silliver is a tablet name associated with silymarin, the extract from milk thistle seeds. Products of this kind are marketed for liver support. That marketing use should not be read as a proven treatment use: NCCIH concludes there is not enough high quality evidence to reach definite conclusions about milk thistle for any health condition, and silymarin is not an established treatment for any liver disease.

Is Silliver a cure for liver disease? No. There is no convincing evidence that silymarin cures, reverses, or treats liver disease. A Cochrane systematic review of trials in alcoholic and hepatitis B or C liver diseases found no significant effect on death, complications of liver disease, or liver structure, and the two NCCIH funded trials in hepatitis C and in steatohepatitis found no benefit. Anyone with liver disease needs a doctor led plan, and a supplement should never replace it.

Does silymarin protect the liver? It has not been shown to. Silymarin shows protective effects in laboratory and animal studies, and some human trials report modest reductions in liver enzyme markers. Those findings fall short of proof of protection in people, because the most rigorous human trials were negative and no convincing effect on long term liver outcomes has been demonstrated. Reading a modest enzyme change as protection is the central misunderstanding this article exists to correct.

Can silymarin detox or cleanse the liver? No evidence supports that claim. The liver continuously processes substances from the blood as part of its normal function. No human trial shows that silymarin cleanses the body, removes unspecified toxins, repairs liver damage, or cancels out the effects of alcohol. Products using detox language are making a marketing claim, not reporting a finding.

Is milk thistle safe? In trials, milk thistle taken by mouth has generally been well tolerated, with digestive effects such as bloating, nausea, diarrhea, and abdominal discomfort as the most commonly reported side effects, and occasional allergic reactions. LiverTox reports that milk thistle has not been implicated in causing liver injury. That general picture does not settle safety for an individual. Little is known about safety in pregnancy or while breastfeeding, people allergic to ragweed family plants should be cautious, and anyone taking medicines should have the combination checked by a doctor or pharmacist first.

Can I take a silymarin tablet if I drink alcohol or take regular medicines? Ask a doctor or pharmacist first, in both cases. Alcohol related liver harm needs its own medical assessment, and no supplement offsets continued heavy drinking. For medicines, laboratory work shows silymarin can affect drug processing pathways, even though clear evidence of major interactions in practice is limited. A pharmacist can check the specific product against your medicine list, which is the only reliable way to answer the question for you.

Why do some studies show lower liver enzymes if silymarin does not work? Enzyme results are the most favorable part of the record, and they are genuinely mixed rather than uniformly negative. Some trials and pooled analyses report reductions in ALT and AST, while the largest and best controlled trials, including the NCCIH funded hepatitis C trial at higher than usual doses, found no advantage over placebo. Small trials also vary in extract, formulation, and quality, and the Cochrane experience, where an apparent mortality benefit vanished in high quality trials only, shows how weak designs can manufacture encouraging signals. A marker change in a small trial is a reason to run a better trial. It is not proof of benefit.

Sources & references

• National Center for Complementary and Integrative Health (NCCIH), Milk Thistle: Usefulness and Safety. Material read: milk thistle is a tall plant with large purple flowers native to Europe and introduced to North America by early colonists; the main constituent of its extract is silymarin, a mixture of compounds; it is promoted as a supplement for liver disorders and diabetes; there is not enough high quality evidence to allow definite conclusions about its effects on health conditions; clinical trial results for liver diseases including alcohol related liver disease, hepatitis B and C, fatty liver disease, and liver problems from chemotherapy, low oxygen, or toxins have been conflicting or too limited for conclusions; two NCCIH funded studies, in hepatitis C and in nonalcoholic steatohepatitis, did not show benefit; a small number of studies suggest extracts may help control blood sugar in type 2 diabetes, mostly from Middle Eastern countries; side effects can include a laxative effect, nausea, diarrhea, abdominal bloating and pain, and occasional allergic reactions; little is known about safety in pregnancy or while breastfeeding. Read via search result excerpts on 3 November 2026. Publication day recheck required.
• National Center for Complementary and Integrative Health (NCCIH), Hepatitis C and Dietary Supplements, including What the Science Says (July 2024). Material read: no dietary supplement has been shown to be effective for hepatitis C; several studies of silymarin in hepatitis C did not find beneficial effects; a 2014 evaluation of five studies with 389 participants showed no improvement in liver function or hepatitis C virus levels; a trial cofunded by NCCIH and NIDDK with 154 participants found higher than usual doses of silymarin over 24 weeks were no better than placebo in improving a measure of liver function; side effects in hepatitis C studies were uncommon and usually mild digestive problems. Read via search result excerpts on 3 November 2026.
• Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and or hepatitis B or C virus liver diseases. Cochrane Database of Systematic Reviews 2007, Issue 4, CD003620, with the Cochrane plain language summary. Material read: 13 randomized clinical trials assessed milk thistle in 915 patients with alcoholic and or hepatitis B or C virus liver diseases; methodological quality was low; milk thistle had no significant effect on mortality (relative risk 0.78, 95 percent confidence interval 0.53 to 1.15), complications of liver disease (relative risk 0.95), or liver histology; liver related mortality was significantly reduced across all trials (relative risk 0.50) but not in high quality trials (relative risk 0.57, confidence interval including no effect); the reviewers questioned the beneficial effects and highlighted the lack of high quality evidence. Read via the Cochrane summary page and secondary reporting of the review via search result excerpts on 3 November 2026.
• Fried MW and colleagues. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 2012;308(3):274-282, as cited and summarized by NCCIH. Material read via NCCIH summaries: 154 participants, silymarin at higher than usual doses for 24 weeks, no better than placebo on the liver function measure studied. Read via search result excerpts on 3 November 2026.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), LiverTox: Clinical and Research Information on Drug Induced Liver Injury, Milk Thistle chapter (updated 21 January 2020). Material read: milk thistle is an herb native to Europe, Asia Minor, and northern Africa, used for centuries for liver conditions; seed extracts contain flavanolignans known collectively as silymarin, largely silybinin, silychristin, and silydianin; in cell culture and animal models silymarin prevented or lessened acute liver injury from many toxins; human studies in chronic liver disease have been promising but inconclusive, and controlled trials in chronic hepatitis C and nonalcoholic fatty liver disease found little or no evidence of benefit; despite wide use, milk thistle has not been implicated in causing serum enzyme elevations or clinically apparent acute liver injury; silymarin has effects on cytochrome P450 enzymes and hepatic transporters in laboratory studies, with little evidence of clinically significant herb drug interactions. Read via search result excerpts on 3 November 2026.
• United States Food and Drug Administration material on dietary supplement regulation under the Dietary Supplement Health and Education Act of 1994, as summarized in regulatory reporting. Material read: dietary supplements are regulated as a category of food; the FDA does not approve supplements for safety and effectiveness, or their labeling, before sale; manufacturers are responsible for ensuring products are safe and labels are truthful; structure and function claims do not require premarket proof of effectiveness, must be notified to the FDA, and must carry the disclaimer that the claim has not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent any disease; the FDA role is primarily postmarket, including facility inspection and action against adulterated or misbranded products. Read via search result excerpts on 3 November 2026. Publication day recheck against the FDA dietary supplements pages required.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) material on cirrhosis symptoms, as reported in clinical summaries citing NIDDK. Material read: early cirrhosis may cause no symptoms; listed symptoms include tiredness, itching, poor appetite, unintended weight loss, and nausea, with yellowing of the skin and eyes, darker urine, leg or abdominal swelling from fluid, easy bruising or bleeding, and confusion among signs of worsening disease. Read via search result excerpts on 3 November 2026. Publication day recheck against the NIDDK cirrhosis page required.